Geneva: The World Health Organization (WHO) has accelerated efforts to identify effective vaccines and treatments against the Bundibugyo strain of Ebola, a rare but dangerous variant currently driving outbreaks in parts of Central Africa. With no approved vaccines or therapies specifically designed for this strain, global health authorities are moving quickly to evaluate promising medical candidates and prevent further spread of the disease.
The latest outbreak has raised concerns among public health experts as cases continue to emerge in the Democratic Republic of the Congo (DRC) and neighbouring Uganda. WHO is now working closely with scientists, governments and international health organisations to fast-track research, clinical trials and potential deployment of vaccines and treatments.
Health officials believe early intervention could play a crucial role in containing the outbreak and reducing fatalities associated with the virus.
Bundibugyo strain poses serious health threat
The Bundibugyo strain is one of several Ebola virus species known to infect humans. While Ebola is widely recognised for causing severe haemorrhagic fever, organ failure and high mortality rates, each strain behaves differently and requires specific medical approaches.
According to health experts, the current Bundibugyo outbreak has an estimated fatality rate ranging between 30 per cent and 50 per cent, making it a major public health concern.
The situation has been complicated by delayed detection of cases, allowing the virus to spread within certain communities before health authorities were able to launch containment measures. Additional challenges such as conflict, population displacement and difficulties in tracing contacts have further increased the risk of transmission.
WHO believes that access to effective vaccines and treatments could significantly improve outbreak response efforts and reduce the disease’s impact.
WHO pushes for rapid clinical trials
To address the growing threat, WHO recently convened a group of international experts to assess available scientific evidence on vaccines and therapies that may be effective against the Bundibugyo strain.
Because no approved medical products currently exist for this specific Ebola variant, WHO has emphasised the need to move the most promising candidates into clinical trials as quickly as possible.
Clinical studies are essential to determine whether vaccines and medicines are both safe and effective under real outbreak conditions. Accelerating these trials could provide valuable information that may support emergency deployment if the outbreak worsens.
The urgency is driven by the increasing number of suspected and confirmed infections reported across affected regions.
Promising vaccine candidates identified
Among the vaccine candidates reviewed, the single-dose rVSV Bundibugyo vaccine developed by the International AIDS Vaccine Initiative (IAVI) emerged as one of the most promising options.
Researchers believe the vaccine has strong potential to protect individuals at high risk of exposure during outbreaks. However, experts estimate that it could take seven to nine months before the vaccine is ready for large-scale clinical testing.
Another leading candidate is the ChAdOx1 Bundibugyo vaccine, developed through collaboration between the University of Oxford and the Serum Institute of India. The vaccine uses technology similar to that employed in the Oxford-AstraZeneca COVID-19 vaccine.
WHO noted that vaccine doses for testing could become available within two to three months, although additional animal studies are still required before broader clinical evaluation can proceed.
Scientists are also exploring whether single-dose or two-dose vaccination strategies would provide the best protection for different population groups.
Existing Ebola vaccine offers limited evidence
WHO experts also examined the potential use of Ervebo, the licensed Ebola vaccine currently used against the Zaire strain of the virus.
While Ervebo has demonstrated effectiveness against that particular strain, researchers found insufficient evidence to confirm that it provides adequate protection against the Bundibugyo variant.
As a result, WHO has recommended that Ervebo should only be used within carefully controlled research settings until more data becomes available.
The assessment highlights the importance of developing strain-specific vaccines capable of addressing different forms of the Ebola virus.
Experimental treatments under evaluation
Alongside vaccine development, WHO has identified several experimental treatments for priority testing.
One of the most promising candidates is MBP134, an antibody-based therapy containing two laboratory-engineered antibodies designed to target Ebola viruses. Early research suggests the treatment is safe and may provide protection against multiple Ebola strains.
Another therapy being considered is Maftivimab, a monoclonal antibody treatment. Experts believe it warrants further investigation because similar antibody-based medicines have proven effective against other Ebola variants in previous outbreaks.
WHO has also prioritised remdesivir, an antiviral drug that has previously been studied during Ebola outbreaks and gained wider recognition during the COVID-19 pandemic.
In addition, health experts are evaluating obeldesivir, an oral antiviral medicine that could potentially be used for individuals exposed to the virus before symptoms develop.
Strengthening preparedness for future outbreaks
The Bundibugyo outbreak has underscored the importance of maintaining preparedness against rare but potentially deadly infectious diseases.
By accelerating vaccine research and treatment development, WHO aims not only to contain the current outbreak but also to strengthen global readiness for future Ebola emergencies.
Public health officials hope that faster access to effective medical tools will improve outbreak response, reduce fatalities and limit the spread of the virus across vulnerable regions.
Conclusion
As the Bundibugyo Ebola outbreak continues to challenge health systems in Central Africa, WHO’s efforts to fast-track vaccines and treatments represent a critical step in combating the disease. With several promising vaccine candidates and experimental therapies under review, global health authorities are working to ensure that effective tools become available as quickly as possible to protect communities and save lives.
Comments are closed.